VOC in Breath Samples for the Diagnosis of IPA

Launched by RAMBAM HEALTH CARE CAMPUS · Aug 1, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to diagnose a serious lung infection called invasive pulmonary aspergillosis (IPA) in patients with acute myeloid leukemia (AML). Traditionally, diagnosing IPA has involved invasive procedures like chest scans and lung tests, which can be uncomfortable for patients. In this study, researchers are looking at breath samples to see if they can detect certain chemicals, called volatile organic compounds (VOCs), that might indicate the presence of IPA. By comparing the breath samples of patients before and after they develop IPA, the goal is to find a non-invasive method for diagnosis that could be easier on patients.

To participate in the trial, you need to be at least 18 years old and have been newly diagnosed with AML or be planning to receive a stem cell transplant. You will also need to have had a chest scan within the last 30 days and be able to provide breath samples. If you join the study, you'll breathe into special bags that will be used to analyze the VOCs in your breath. This research could lead to better, less invasive ways to diagnose IPA, which is important for deciding the best treatment for patients with weakened immune systems.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • New diagnosis of acute myeloid leukemia AND/OR planned hematopoietic stem cells transplantation (HCT)
• • Chest CT performed within 30 days from sampling
• • 18 years of age or older
• • The ability to provide tidal breath samples totalling 10L directly into a Tedlar bag
• Exclusion Criteria:
• • Any condition impairing the patient's ability to provide informed consent